AGP Executive Report
Last update: 13 minutes agoMacau Drug Approvals: ACA Pharma and Azurity say both Feraheme® and Ferabright™ have received regulatory approval in Macau, a fresh boost for access to ferumoxytol-based therapies. Cancer Treatment Update: HUTCHMED and Innovent report NMPA approval in China for ELUNATE® (fruquintinib) plus TYVYT® (sintilimab) for certain renal cell carcinoma patients after prior VEGFR-TKI therapy. Health Safety Watch: Macau’s Health Bureau is stepping up Ebola readiness after WHO’s emergency declaration for parts of the DRC and Uganda, while stressing the immediate risk to Macau is low. Heart Health Debate: New research tied “optimal” heart protection to much higher exercise levels—up to 560–610 minutes weekly—pushing beyond the usual 150-minute guidance. Local Health Services: The Municipal Kennel is set to shift to a temporary site from June 1 during renovations, with some appointment types paused but key services continuing.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
